255 related articles for article (PubMed ID: 14616979)
1. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
[TBL] [Abstract][Full Text] [Related]
2. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
3. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS).
Politou M; Terpos E; Anagnostopoulos A; Szydlo R; Laffan M; Layton M; Apperley JF; Dimopoulos MA; Rahemtulla A
Br J Haematol; 2004 Sep; 126(5):686-9. PubMed ID: 15327520
[TBL] [Abstract][Full Text] [Related]
4. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
5. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
7. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
[TBL] [Abstract][Full Text] [Related]
8. The influence of Lys3Asn polymorphism in the osteoprotegerin gene on bone mineral density in Chinese postmenopausal women.
Zhao HY; Liu JM; Ning G; Zhao YJ; Zhang LZ; Sun LH; Xu MY; Uitterlinden AG; Chen JL
Osteoporos Int; 2005 Dec; 16(12):1519-24. PubMed ID: 15782282
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial.
Voskaridou E; Anagnostopoulos A; Konstantopoulos K; Stoupa E; Spyropoulou E; Kiamouris C; Terpos E
Haematologica; 2006 Sep; 91(9):1193-202. PubMed ID: 16956818
[TBL] [Abstract][Full Text] [Related]
10. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
[TBL] [Abstract][Full Text] [Related]
11. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
Terpos E; Politou M; Szydlo R; Nadal E; Avery S; Olavarria E; Kanfer E; Goldman JM; Apperley JF; Rahemtulla A
Leukemia; 2004 Aug; 18(8):1420-6. PubMed ID: 15215875
[TBL] [Abstract][Full Text] [Related]
14. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
15. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.
Jung K; Lein M; Ringsdorf M; Roigas J; Schnorr D; Loening SA; Staack A
J Urol; 2006 Oct; 176(4 Pt 1):1326-31. PubMed ID: 16952623
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
[TBL] [Abstract][Full Text] [Related]
18. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
20. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
